Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX130 in advanced relapsed or refractory clear cell renal cell carcinoma
NL-OMON54482Phase 2Completed
- Sponsor
- CRISPR Therapeutics
- Start
- Mar 2021
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CTX130 in clear cell renal cell carcinoma (ccRCC) (5 arms), sponsored by CRISPR Therapeutics. Primary endpoints: Dose-limiting toxicities in single-dose escalation, Adverse events after multiple doses and 1 more. Started Mar 2021; status: completed.
02
Drugs
CTX130
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NL-OMON54482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54482.